FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970111821> ?p ?o ?g. }

• W1970111821 endingPage "2732" @default.
• W1970111821 startingPage "2726" @default.
• W1970111821 abstract "BACKGROUND. Previous prognostic studies in primary myelofibrosis have focused on risk factors for overall survival and have resulted in the establishment of several prognostic scoring systems. However, to the authors' knowledge, information regarding risk factors for leukemic transformation in primary myelofibrosis is limited. METHODS. The current retrospective study examined clinical variables at the time of diagnosis and specific treatment modalities for their effect on leukemic transformation in 311 patients with primary myelofibrosis who were seen at the Mayo Clinic. RESULTS. Univariate analysis of parameters at the time of diagnosis revealed a significant association between inferior leukemia-free survival and a peripheral blood blast percentage ≥3 (P < .0001), a platelet count <100 × 109/L (P = .004), a monocyte count ≥1 × 109/L (P = .02), the presence of hypercatabolic symptoms (P = .03), a low hemoglobin level (P = .04), and a high leukocyte count (P = .04). The first 2 parameters were found to maintain their statistical significance during multivariate analysis. Neither leukemia-free nor overall survival was found to be affected by the presence of <3% peripheral blood blasts or JAK2V617F mutation. The evaluation of treatment effect on leukemic transformation unexpectedly revealed a significant and independent association with previous therapy with either erythropoiesis‒stimulating agents (P = .004) or danazol (P = .007), even when the aforementioned prognostic indicators at the time of diagnosis were added as covariates to the multivariate model. In contrast, leukemia-free survival was not found to be affected by a treatment history with hydroxyurea, thalidomide, or other drugs. CONCLUSIONS. A peripheral blood blast percentage ≥3 and/or a platelet count <100 × 109/L at the time of diagnosis were found to be strong and independent predictors of leukemic transformation in patients with primary myelofibrosis. The unexpected association between leukemic transformation and a history of treatment with erythropoiesis‒stimulating agents or danazol requires validation by prospective studies. Cancer 2008. © 2008 American Cancer Society." @default.
• W1970111821 created "2016-06-24" @default.
• W1970111821 creator A5008437556 @default.
• W1970111821 creator A5016216479 @default.
• W1970111821 creator A5024612499 @default.
• W1970111821 creator A5039057642 @default.
• W1970111821 creator A5068134983 @default.
• W1970111821 creator A5069117871 @default.
• W1970111821 creator A5082992202 @default.
• W1970111821 date "2008-06-15" @default.
• W1970111821 modified "2023-09-27" @default.
• W1970111821 title "Risk factors for leukemic transformation in patients with primary myelofibrosis" @default.
• W1970111821 cites W1517716082 @default.
• W1970111821 cites W1581000033 @default.
• W1970111821 cites W1768890565 @default.
• W1970111821 cites W1980464575 @default.
• W1970111821 cites W1997867585 @default.
• W1970111821 cites W2002189627 @default.
• W1970111821 cites W2014268597 @default.
• W1970111821 cites W2022159066 @default.
• W1970111821 cites W2025606645 @default.
• W1970111821 cites W2028961479 @default.
• W1970111821 cites W2039956148 @default.
• W1970111821 cites W2045831870 @default.
• W1970111821 cites W2051111824 @default.
• W1970111821 cites W2051224868 @default.
• W1970111821 cites W2052293448 @default.
• W1970111821 cites W2056116861 @default.
• W1970111821 cites W2073653195 @default.
• W1970111821 cites W2079474383 @default.
• W1970111821 cites W2085920715 @default.
• W1970111821 cites W2087623186 @default.
• W1970111821 cites W2088915934 @default.
• W1970111821 cites W2091061603 @default.
• W1970111821 cites W2117385094 @default.
• W1970111821 cites W2126715987 @default.
• W1970111821 cites W2144703394 @default.
• W1970111821 cites W2149622082 @default.
• W1970111821 cites W2163066827 @default.
• W1970111821 cites W2163663635 @default.
• W1970111821 cites W2164837040 @default.
• W1970111821 cites W3114368461 @default.
• W1970111821 cites W4237139322 @default.
• W1970111821 doi "https://doi.org/10.1002/cncr.23505" @default.
• W1970111821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18404742" @default.
• W1970111821 hasPublicationYear "2008" @default.
• W1970111821 type Work @default.
• W1970111821 sameAs 1970111821 @default.
• W1970111821 citedByCount "112" @default.
• W1970111821 countsByYear W19701118212012 @default.
• W1970111821 countsByYear W19701118212013 @default.
• W1970111821 countsByYear W19701118212014 @default.
• W1970111821 countsByYear W19701118212015 @default.
• W1970111821 countsByYear W19701118212016 @default.
• W1970111821 countsByYear W19701118212017 @default.
• W1970111821 countsByYear W19701118212018 @default.
• W1970111821 countsByYear W19701118212019 @default.
• W1970111821 countsByYear W19701118212020 @default.
• W1970111821 countsByYear W19701118212021 @default.
• W1970111821 countsByYear W19701118212022 @default.
• W1970111821 countsByYear W19701118212023 @default.
• W1970111821 crossrefType "journal-article" @default.
• W1970111821 hasAuthorship W1970111821A5008437556 @default.
• W1970111821 hasAuthorship W1970111821A5016216479 @default.
• W1970111821 hasAuthorship W1970111821A5024612499 @default.
• W1970111821 hasAuthorship W1970111821A5039057642 @default.
• W1970111821 hasAuthorship W1970111821A5068134983 @default.
• W1970111821 hasAuthorship W1970111821A5069117871 @default.
• W1970111821 hasAuthorship W1970111821A5082992202 @default.
• W1970111821 hasBestOaLocation W19701118211 @default.
• W1970111821 hasConcept C126322002 @default.
• W1970111821 hasConcept C143998085 @default.
• W1970111821 hasConcept C144301174 @default.
• W1970111821 hasConcept C167135981 @default.
• W1970111821 hasConcept C2778248108 @default.
• W1970111821 hasConcept C2778461978 @default.
• W1970111821 hasConcept C2780007613 @default.
• W1970111821 hasConcept C2780076729 @default.
• W1970111821 hasConcept C2780240888 @default.
• W1970111821 hasConcept C2780817109 @default.
• W1970111821 hasConcept C38180746 @default.
• W1970111821 hasConcept C50382708 @default.
• W1970111821 hasConcept C71924100 @default.
• W1970111821 hasConcept C90924648 @default.
• W1970111821 hasConceptScore W1970111821C126322002 @default.
• W1970111821 hasConceptScore W1970111821C143998085 @default.
• W1970111821 hasConceptScore W1970111821C144301174 @default.
• W1970111821 hasConceptScore W1970111821C167135981 @default.
• W1970111821 hasConceptScore W1970111821C2778248108 @default.
• W1970111821 hasConceptScore W1970111821C2778461978 @default.
• W1970111821 hasConceptScore W1970111821C2780007613 @default.
• W1970111821 hasConceptScore W1970111821C2780076729 @default.
• W1970111821 hasConceptScore W1970111821C2780240888 @default.
• W1970111821 hasConceptScore W1970111821C2780817109 @default.
• W1970111821 hasConceptScore W1970111821C38180746 @default.
• W1970111821 hasConceptScore W1970111821C50382708 @default.
• W1970111821 hasConceptScore W1970111821C71924100 @default.
• W1970111821 hasConceptScore W1970111821C90924648 @default.

• next